← Human Trials & Peer-Reviewed Studies
Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial
Plain-language guide to PMID 27042193 (2016): randomized controlled trial study of Enfuvirtide in 2 patients.
Key Facts
- PMID
- 27042193
- Journal
- AIDS research and therapy
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- de Castro N et al. (8 authors)
- DOI
- 10.1186/s12981-016-0101-3
What This Study Did, in Plain Language
What Was Tested
Researchers studied Enfuvirtide in this randomized controlled trial publication.
In the ANRS EASIER trial where treatment-experienced patients switched from enfuvirtide (ENF) to raltegravir (RAL), a high incidence of transaminase elevation was reported in the RAL arm.
Who Took Part
The abstract describes 2 patients taking part.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
The researchers compared the incidence of emergent liver enzyme elevations (LEE) of grade 2 or more among patients randomized to the maintenance ENF arm or the switch RAL arm up to W24.
How the Study Was Run
In design terms this was a randomized study.
The patients were allocated by chance, so the Enfuvirtide group and the comparison group should start out alike.
The researchers also assessed the overall incidence of LEE over the 48-week duration of the trial and baseline risk factors for grade 2 or more alanine aminotransferase (ALT) elevation using univariate and multivariate analyses.
What Was Measured
The subject headings attached to it are Alanine Transaminase, Chemical and Drug Induced Liver Injury, Drug Substitution, Enfuvirtide, HIV Envelope Protein gp41, HIV Fusion Inhibitors and HIV Infections.
The authors tagged it with the keywords Liver enzymes, Raltegravir, Tipranavir and Transaminases.
What This Means in Plain Language
The paper is a randomized study of Enfuvirtide in 2 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2016 (AIDS research and therapy), a journal based in England.
More context: the Enfuvirtide compound page, all human trials.
Our Notes on the Compound
Enfuvirtide: A 36-amino-acid peptide (Fuzeon) that blocks HIV from entering cells.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.